Multiply Labs raises $75M for robotic drug manufacturing

Multiply Labs, a startup developing automation equipment for drugmakers, has raised $75 million in a Series B round. The deal was led by prominent medical researcher Patrick Soon-Shiong, with participation from more than half a dozen other backers, including AstraZeneca and robotics supplier Teradyne.

The funding comes as pharmaceutical companies seek ways to streamline production for complex therapies. Some in the industry suggest that automation could address challenges like consistency and cost, particularly for tasks that typically rely on manual labor or specialized machinery. If successful, such systems might offer advantages in adapting to different drug formulations, though this remains speculative.

The involvement of high-profile investors may reflect broader interest in applying robotics to pharmaceutical manufacturing. While some backers have previously focused on biotech, this deal could indicate a shift toward automation as a potential solution for production bottlenecks. AstraZeneca’s participation might suggest interest from large pharma, though no commercial deployment has been confirmed.

The size of the round—larger than some recent funding announcements in the robotics space—could point to investor enthusiasm for niche automation applications. Pharmaceutical manufacturing presents unique challenges, including regulatory requirements and precision at small scales, which may limit competition. However, without disclosed revenue or customer details, the startup’s traction remains unclear.

For now, the funding highlights the possibility that robotics could play a role beyond traditional industrial or warehouse applications. Whether such systems can reliably meet the demands of a highly regulated environment is yet to be determined.

Sources: siliconangle.com